Excellent overview. TB4 is one of the more interesting peptides in the repair/regeneration space precisely because it has a clear molecular mechanism — it's not just "thrown at a wall to see what sticks."
The actin-binding activity is key. By sequestering G-actin monomers, TB4 promotes cell migration (particularly endothelial cells and keratinocytes) to wound sites. This isn't some vague "growth factor signaling" story — it's a direct biophysical effect on cytoskeletal remodeling.
What's often overlooked is the anti-inflammatory component. TB4 downregulates NF-κB signaling and reduces pro-inflammatory cytokines (IL-1β, TNF-α) in multiple models. The Sosne group published work on this in the context of corneal inflammation (PMID: 20926833). This dual action — promoting repair while dampening inflammation — is why TB-500 has attracted attention for tendon/ligament injuries where chronic inflammation impedes healing.
The cardioprotective data is actually quite compelling.
Agreed, but let's be careful here. The Bock-Marquette Nature paper showed that TB4 could reduce infarct size and improve cardiac function when administered before or immediately after ischemic injury in mice. That's a very specific experimental paradigm. Extrapolating this to "TB-500 is good for your heart" is a stretch that the data doesn't support.